-
公开(公告)号：US11136404B2
公开(公告)日：2021-10-05
申请号：US16284811
申请日：2019-02-25
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd , Memorial Sloan-Kettering Cancer Center
发明人： Marc Van Dijk , Ekaterina V. Breous-Nystrom , Volker Seibert , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Hao Tang , David A. Savitsky , Jeremy Waight , Nicholas S. Wilson
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06 , G01N33/68 , A61K39/00
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
公开(公告)号：US11447557B2
公开(公告)日：2022-09-20
申请号：US15781043
申请日：2016-12-02
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Nicholas S. Wilson , Jeremy D. Waight , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Ekaterina V. Breous-Nystrom , Volker Seibert , Takemasa Tsuji , Olivier Léger , Dennis J. Underwood , Marc Van Dijk
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06
摘要： The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.
-
公开(公告)号：US11332536B2
公开(公告)日：2022-05-17
申请号：US16784469
申请日：2020-02-07
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Marc Van Dijk , Ekaterina V. Breous-Nystrom , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Hao Tang , David A. Savitsky , Nicholas S. Wilson
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
公开(公告)号：US20190284291A1
公开(公告)日：2019-09-19
申请号：US16284811
申请日：2019-02-25
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd , Memorial Sloan-Kettering Cancer Center
发明人： Marc VAN DIJK , Ekaterina V. Breous-Nystrom , Volker Seibert , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Hao Tang , David A. Savitsky , Jeremy Waight , Nicholas S. Wilson
IPC分类号： C07K16/28 , G01N33/68 , A61K45/06 , A61K39/395
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
公开(公告)号：US20220098316A1
公开(公告)日：2022-03-31
申请号：US17446706
申请日：2021-09-01
申请人： AGENUS INC. , Ludwig Institute for Cancer Research Ltd. , Memorial Sloan-Kettering Cancer Center
发明人： Marc VAN DIJK , Ekaterina V. Breous-Nystrom , Volker Seibert , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Hao Tang , David A. Savitsky , Jeremy Waight , Nicholas S. Wilson
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06 , G01N33/68
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
公开(公告)号：US20160347847A1
公开(公告)日：2016-12-01
申请号：US15148720
申请日：2016-05-06
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd. , Memorial Sloan-Kettering Cancer Center
发明人： Marc VAN DIJK , Ekaterina V. Breous-Nystrom , Volker Seibert , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Hao Tang , David A. Savitsky , Jeremy Waight , Nicholas S. Wilson
IPC分类号： C07K16/28 , A61K45/06 , G01N33/68 , A61K39/395
CPC分类号： C07K16/2878 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2875 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/524 , C07K2317/56 , C07K2317/565 , C07K2317/70 , C07K2317/71 , C07K2317/74 , C07K2317/75 , C07K2317/92 , G01N33/6863 , G01N2333/70578
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
摘要翻译： 本公开提供了特异性结合人OX40受体（OX40）的抗体和包含此类抗体的组合物。 在具体方面，抗体特异性结合人OX40并调节OX40活性，例如增强，激活或诱导OX40活性，或减少，失活或抑制OX40活性。 本公开还提供了通过施用特异性结合人OX40并调节OX40活性，例如增强，激活或诱导OX40活性的抗体来治疗疾病如癌症的方法。 还提供了通过施用与人OX40特异性结合并调节OX40活性的抗体（例如减少，失活或抑制OX40活性）来治疗自身免疫性或炎性疾病或病症的方法。
-
公开(公告)号：US11472883B2
公开(公告)日：2022-10-18
申请号：US16808074
申请日：2020-03-03
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Marc Van Dijk , Ekaterina V. Breous-Nystrom , Volker Seibert , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Hao Tang , David A. Savitsky , Jeremy Waight , Nicholas S. Wilson
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
公开(公告)号：US11359028B2
公开(公告)日：2022-06-14
申请号：US16407835
申请日：2019-05-09
申请人： Agenus Inc. , Memorial Sloan-Kettering Cancer Center , Ludwig Institute for Cancer Research Ltd.
发明人： Nicholas S. Wilson , Jeremy D. Waight , Dennis J. Underwood , Ekaterina V. Breous-Nystrom , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Marc Van Dijk
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies. The antibodies disclosed herein modulate OX40 and/or GITR activity e.g., enhance, activate, induce, reduce, deactivate, or inhibit OX40 and/or GITR activity. The present disclosure also provides methods for treating disorders, such as cancer, autoimmune diseases or disorders, or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and/or human GITR and modulates OX40 and/or GITR activity.
-
公开(公告)号：US10259882B2
公开(公告)日：2019-04-16
申请号：US15148720
申请日：2016-05-06
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd. , Memorial Sloan-Kettering Cancer Center
发明人： Marc Van Dijk , Ekaterina V. Breous-Nystrom , Gerd Ritter , David Schaer , Daniel Hirschhorn-Cymerman , Taha Merghoub , Hao Tang , David A. Savitsky , Nicholas S. Wilson
IPC分类号： A61K39/395 , C07K16/28 , A61K45/06 , G01N33/68 , A61K39/00
摘要： The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.033 秒)
